In the ever-evolving landscape of haircare, Nexgen Labs has pioneered a groundbreaking autologous therapy for hair growth – Folligen AGF. With a legacy founded by Mrs Premlata sharma from a family of dermatologists, Nexgen Labs has revolutionized the industry, propelling autologous therapies to new heights and earning a reputation as a trailblazer in India and beyond.
What sets Nexgen Labs apart is not just its pioneering spirit but also its commitment to regulatory standards. Folligen AGF is registered with the Central Drugs Standard Control Organization (CDSCO), ensuring the highest quality and safety standards for patients seeking a reliable solution for hair growth.
Nexgen Labs stands out as the first company in India to delve into autologous therapies, ushering in a new era of personalized and result-driven solutions. Folligen AGF, the flagship product, has become a bestseller, benefiting over 100,000 patients worldwide. This innovative therapy has expanded its reach to countries like Mauritius, Sri Lanka, Dubai, and Canada, making it a global phenomenon.
Treatment Efficacy:
Folligen AGF boasts a remarkable treatment protocol, addressing hair fall and promoting hair growth in just three sessions. With one session per month over three months, patients experience tangible results that go beyond conventional methods. This efficiency has made Folligen AGF a preferred choice among individuals seeking a swift and effective solution to their hair concerns.
What makes Folligen AGF stand out in the crowded market of haircare therapies is its advanced technology.
Unlike traditional PRP (Platelet-Rich Plasma) therapies, Folligen AGF takes a step further by offering zero platelets.
The therapy optimally extracts growth factors like PDGF, EGF, IGF, among others, from the patient’s blood and then reinjects these potent growth factors directly into the treatment area.
A key differentiator is Folligen AGF’s activation of growth factors in vitro.
While PRP therapies release growth factors inside the body, Folligen AGF’s advanced approach ensures precise activation outside the body, enhancing the therapeutic impact on hair growth.
This novel method sets Folligen AGF apart as a cutting-edge solution in the realm of autologous therapies.
Nexgen Labs, driven by a commitment to innovation and patient well-being, has transformed the landscape of haircare with Folligen AGF. With its unique treatment approach, global presence, and CDSCO registration, Folligen AGF has become a symbol of trust for those seeking a revolutionary and result-driven autologous therapy for hair growth. As the industry continues to evolve, Nexgen Labs remains at the forefront, leading the charge towards a future where personalized solutions redefine the possibilities of healthy, vibrant hair.
